News | July 22, 2021
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Sun Pharma has committed Rs. 100 crores towards these initiatives
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The company has reported total income of Rs.355.43 crores during FY 2020-21
Subscribe To Our Newsletter & Stay Updated
